Ratings
0
Nobody has rated this yet. Be the first!
Works
8
Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials.
Evaluation of commercial kits for purification of circulating free DNA
Paradoxical oncogenesis: are all BRAF inhibitors equal?
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy
p14ARF interacts with the SUMO-conjugating enzyme Ubc9 and promotes the sumoylation of its binding partners.
Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition.
Frequent loss of heterozygosity targeting the inactive X chromosome in melanoma
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor
